New shot for schizophrenia shows promise in early safety trial
NCT ID NCT06627413
First seen Apr 11, 2026 · Last updated Jun 18, 2026 · Updated 16 times
Summary
This early-stage study tested a long-acting injectable form of the drug lumateperone in 52 adults with stable schizophrenia or schizoaffective disorder. Researchers gave a single shot and monitored how the drug moved through the body, as well as any side effects. The goal was to see if this monthly-like injection could be a safe and convenient option for ongoing symptom control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinical Site 1
Marlton, New Jersey, 08053, United States
-
Clinical Site 2
Los Alamitos, California, 90720, United States
-
Clinical Site 3
Atlanta, Georgia, 30331, United States
-
Clinical Site 4
Decatur, Georgia, 30030, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.